A once-daily, extended-release formulation that combines dapagliflozin and metformin (Xigduo XR) has been approved for the treatment of type 2 diabetes in adults, announced manufacturer AstraZeneca. The two medications have complementary modes of action, the company explained in a press release. The new formulation is intended to be used as an adjunct to diet and exercise for patients considered suitable candidates for treatment with both medications. It will be available in several dosage strengths of dapagliflozin and metformin. The treatment has been especially good in clinical trials at treating newly diagnosed diabetes patients. Diabetes is a common and growing trend in workers’ comp co-morbidities.
Read more about the new drug here.